Optocain (Mepivacaine Hydrochloride)

Mepivacaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing the influx of sodium ions that is required for the generation and propagation of action potentials. This interruption stops nerve signals in the targeted area, producing a reversible loss of sensation.

The exact dose of Optocain is determined by the prescribing dentist based on the specific procedure, patient weight, age, and overall health. Clinicians calculate the amount needed to achieve adequate anesthesia while staying within recommended safety limits.

Safety data for mepivacaine hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating clinician in consultation with the patient.

To request Optocain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Optocain (mepivacaine) offers a rapid onset of anesthesia similar to lidocaine but typically provides a slightly longer duration without the need for vasoconstrictors. It is an amide‑type anesthetic, making it less prone to allergic reactions than ester‑type agents.

Optocain should be stored below 25 °C in its original packaging, protected from light and moisture. Keep the vial sealed until use, and discard any solution that appears discolored or contains particles.

Optocain is supplied as a sterile solution for injection. The dentist injects the solution directly into the periodontal ligament, mucosal tissue, or nerve bundle using a standard dental syringe, following aseptic technique and appropriate dosage calculations.

Serious risks include allergic reactions (rash, swelling, anaphylaxis), cardiovascular effects such as arrhythmias or hypotension, and central nervous system toxicity that can manifest as seizures or prolonged numbness. Immediate medical attention is required if any of these occur.

Patients with a known hypersensitivity to mepivacaine, other amide‑type local anesthetics, or any component of the formulation should avoid Optocain. Caution is also advised for individuals with severe cardiac disease, uncontrolled hypertension, or those taking interacting medications such as MAO inhibitors.